CA3035897A1 - Gamma-ketoaldehyde scavengers and compositions thereof for use in treatment of liver diseases - Google Patents

Gamma-ketoaldehyde scavengers and compositions thereof for use in treatment of liver diseases Download PDF

Info

Publication number
CA3035897A1
CA3035897A1 CA3035897A CA3035897A CA3035897A1 CA 3035897 A1 CA3035897 A1 CA 3035897A1 CA 3035897 A CA3035897 A CA 3035897A CA 3035897 A CA3035897 A CA 3035897A CA 3035897 A1 CA3035897 A1 CA 3035897A1
Authority
CA
Canada
Prior art keywords
optionally substituted
membered ring
ring containing
liver
hoba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3035897A
Other languages
English (en)
French (fr)
Inventor
John Rathmacher
Naji Abumrad
Charles Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Technologies LLC
Original Assignee
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies LLC filed Critical Metabolic Technologies LLC
Publication of CA3035897A1 publication Critical patent/CA3035897A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3035897A 2016-09-06 2017-09-06 Gamma-ketoaldehyde scavengers and compositions thereof for use in treatment of liver diseases Pending CA3035897A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US62/383,895 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US62/410,133 2016-10-19
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Publications (1)

Publication Number Publication Date
CA3035897A1 true CA3035897A1 (en) 2018-03-15

Family

ID=61562136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3035897A Pending CA3035897A1 (en) 2016-09-06 2017-09-06 Gamma-ketoaldehyde scavengers and compositions thereof for use in treatment of liver diseases

Country Status (8)

Country Link
US (3) US20180153827A1 (https=)
EP (1) EP3510014B1 (https=)
JP (3) JP7189127B2 (https=)
CN (2) CN110177771B (https=)
AU (1) AU2017324935B2 (https=)
CA (1) CA3035897A1 (https=)
MX (1) MX2019002579A (https=)
WO (1) WO2018048932A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
PL3914359T3 (pl) 2019-01-25 2025-07-28 Mti Biotech, Inc. Pochodne salicyloaminy przyłączone do trifenylofosfonium
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197689T3 (es) * 1998-10-22 2004-01-01 University Of South Carolina Procedimientos para inhibir complicaciones diabeticas.
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
US10975033B2 (en) 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
KR20170088883A (ko) * 2014-11-11 2017-08-02 벤더르빌트 유니버시티 급성 신장 손상을 제한하기 위한 방법
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver

Also Published As

Publication number Publication date
MX2019002579A (es) 2020-02-05
WO2018048932A1 (en) 2018-03-15
EP3510014A4 (en) 2020-05-20
AU2017324935B2 (en) 2021-10-21
JP2025032245A (ja) 2025-03-11
EP3510014B1 (en) 2026-04-29
JP2023022236A (ja) 2023-02-14
US20180153827A1 (en) 2018-06-07
CN119345198A (zh) 2025-01-24
US12383515B2 (en) 2025-08-12
JP7189127B2 (ja) 2022-12-13
EP3510014A1 (en) 2019-07-17
US20230181494A1 (en) 2023-06-15
CN110177771A (zh) 2019-08-27
AU2017324935A1 (en) 2019-03-28
BR112019004404A2 (pt) 2019-05-28
JP2019526598A (ja) 2019-09-19
US20250360094A1 (en) 2025-11-27
CN110177771B (zh) 2022-12-13

Similar Documents

Publication Publication Date Title
US12383515B2 (en) Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
Suzuki et al. Green coffee bean extract and its metabolites have a hypotensive effect in spontaneously hypertensive rats
Niu et al. Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice
CN111182904A (zh) 包含acc抑制剂的组合治疗
Sharawy et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition
Arai et al. Acrolein, a highly toxic aldehyde generated under oxidative stress in vivo, aggravates the mouse liver damage after acetaminophen overdose
El-Gazar et al. Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats
KR20060129082A (ko) 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
Khazaei et al. Protective effects of sulfated polysaccharides from Enteromorpha intestinalis on oxidative stress, liver iron overload and Ferroptosis in Zebra fish exposed to ethanol
Svalbe et al. Mildronate treatment improves functional recovery following middle cerebral artery occlusion in rats
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Abbas et al. Pentoxifylline and cilostazol against rat heart injuries induced by doxorubicin
Griggs et al. Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea
HK40012573B (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
HK40012573A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
WO2016138132A1 (en) Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation
CN114470217B (zh) 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
BR112019004404B1 (pt) Uso de um composto
Garbuzenko Perspectives of drug therapy for non-alcoholic steatohepatitis-related liver fibrosis
Alblooshi THE EFFECT OF LICOGLIFLOZIN (SGLT1/2 INHIBITOR) ON DIABETES AND CARDIAC COMPLICATIONS
Hao et al. Scoparone attenuates cholestatic liver injury through regulating hepatic bile acid metabolism, ameliorating periductal fibrosis and inhibiting inflammatory response
EP3678650A1 (en) Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
Kumar et al. EXPERIMENTAL VALIDATION OF ANTI-DIABETIC AND ANTIOXIDANT POTENTIAL OF T. CORDIFOLIA STEMS (M.): AN INDIGENOUS MEDICINAL PLANT.
Kamal Anti-oxidant and anti-inflammatory effects of vildagliptin in non-alcoholic fatty liver disease of mice
Tobin The Key to Diethylene Glycol Toxicity Lies in the Transport of Its Toxic Metabolite Diglycolic Acid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220901

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241003

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250604

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250604

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250904

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251021